Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KARMA-Dep: Ketamine for Depression
NCT03256162Phase 1Completed
- Sponsor
- St Patrick's Mental Health Services
- Start
- Sep 2017
- Primary completion
- Sep 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ketamine in major depressive disorder (MDD) and bipolar disorder (BD) (2 arms), sponsored by St Patrick's Mental Health Services. Primary endpoint: Hamilton Rating Scale for Depression-24 Item Version at 15 weeks. Started Sep 2017; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)
Beyond the preview
Go deeper on NCT03256162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03256162.